Purchase this article with an account.
C. Bergstrom, G.B. Hubbard, III; Intravitreal Triamcinolone for Exudative Retinal Detachment Associated With Coats Disease . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4278.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effectiveness of intravitreal triamcinolone in reducing subretinal fluid in patients with bullous, exudative retinal detachments associated with Coats disease.
A retrospective chart review was performed on five consecutive patients with Coats disease treated with intravitreal triamcinolone for bullous, exudative retinal detachments.
Five male patients, ages 3 to 12, with exudative retinal detachment secondary to Coats disease, were given an intravitreal injection of triamcinolone (4mg/0.1cc) using sterile technique during examination under general anesthesia. Four patients had not received any previous treatment and were considered poor candidates for standard cryoablation due to large amounts of subretinal fluid. One patient had three previous cryotherapy treatments yet still retained large amounts of subretinal fluid. One of the five patients received cryotherapy at the time of injection. Ultrasonography was performed on patients prior to triamcinolone injection. Patients have been followed for an average of 18 weeks (range 6–52). All patients showed significant reduction in subretinal fluid on repeat EUA clinically and ultrasonographically. Each patient underwent successful cryoablation on average 6 weeks after injection. One patient developed elevated intraocular pressure that was controlled with topical medication.
Intravitreal triamcinolone can reduce subretinal fluid in patients with exudative retinal detachments due to Coats disease and can facilitate subsequent cryoablation of retinal telangiectasias.
This PDF is available to Subscribers Only